Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.35 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.35 |
| ▸ | CYBB | P04839 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14742456 | 0.96 | ALDH1A1 (0.42) | ALDH1A1KDM4ETSHRHSD17B10ALOX15 | |
| SCHEMBL16965741 | 0.95 | ALDH1A1 (0.41) | ALDH1A1KDM4ETSHRHSD17B10ALOX15 | |
| SCHEMBL16965449 | 0.95 | ALDH1A1 (0.41) | ALDH1A1KDM4ETSHRHSD17B10ALOX15 | |
| SCHEMBL20994189 | 0.94 | ALDH1A1 (0.44) | ALDH1A1KDM4ETSHRHSD17B10ALOX15 | |
| Hydrochloric Acid SCHEMBL9938484 | 0.93 | ALDH1A1 (0.40) | ALDH1A1KDM4ETSHRHSD17B10ALOX15 | |
| SCHEMBL29249166 | 0.91 | MAPT (0.40) | ALDH1A1KDM4ETSHRHSD17B10ALOX15 | |
| SCHEMBL1701442 | 0.90 | ALDH1A1 (0.41) | ALDH1A1KDM4ETSHRHSD17B10ALOX15 | |
| SCHEMBL30594614 | 0.90 | ALDH1A1 (0.41) | ALDH1A1KDM4ETSHRHSD17B10ALOX15 | |
| Formaldehyde SCHEMBL16965859 | 0.90 | EPHX1 (0.40) | ALDH1A1KDM4ETSHRHSD17B10ALOX15 | |
| Formaldehyde SCHEMBL16965494 | 0.90 | EPHX1 (0.40) | ALDH1A1KDM4ETSHRHSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4490151-A1 | SOLID FORMS, SALTS, AND PROCESSES OF PREPARATION OF A CDK2 INHIBITOR | Incyte Corporation (US) | 2025-01-15 | — | — | EP | disclosed |
| EP-3995492-B1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023172921-A1 | SOLID FORMS, SALTS, AND PROCESSES OF PREPARATION OF A CDK2 INHIBITOR | INCYTE CORPORATION (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-3166923-B1 | PROCESS FOR PREPARING SUBSTITUTED PHENYLALKANES | SpecGx LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20220389310-A1 | LUMINESCENT MATERIALS AND METHODS THEREOF | UNIVERSITY OF WASHINGTON (US) | 2022-12-08 | — | — | US | disclosed |
| EP-3995492-A1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2022-05-11 | — | — | EP | disclosed |
| EP-3319941-B1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2021-12-29 | — | — | EP | disclosed |
| WO-2021062035-A1 | LUMINESCENT MATERIALS AND METHODS THEREOF | UNIVERSITY OF WASHINGTON (US) | 2021-04-01 | — | — | WO | disclosed |
| US-10472392-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3392253-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | Gilead Sciences, Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-2861601-B1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-2859009-B1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170190737-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20170190734-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | Selcia Ltd. (GB) | 2017-07-06 | — | — | US | disclosed |
| EP-2861604-B1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170008832-A1 | TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | MALLINCKRODT ENTERPRISES LLC | 2017-01-12 | — | — | US | disclosed |
| US-20160220633-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| WO-2016004413-A2 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2013041106-A1 | SYSTEM PROVIDING CONTROLLED DELIVERY OF GASEOUS 11CO FOR CARBONYLATION REACTIONS IN THE PREPARATION OF RADIOPHARMACEUTICALS FOR PET IMAGING | AARHUS UNIVERSITET (DK) | 2013-03-28 | — | — | WO | disclosed |
| WO-2012079583-A1 | SYSTEM PROVIDING CONTROLLED DELIVERY OF GASEOUS CO FOR CARBONYLATION REACTIONS | AARHUS UNIVERSITET (DK) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190737-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | ALDH1A1 1076/4885KDM4E 1883/4885TSHR 3768/4885 |
| US-10472392-B2 | Macrocyclic inhibitors of flaviviridae viruses | HAVCR2, ZC3HAV1, HCCS | ALDH1A1 1076/4885KDM4E 1883/4885TSHR 3768/4885 |
| US-20170008832-A1 | TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | PNMT, CYP1B1, UGT2B7 | ALDH1A1 462/4885KDM4E 618/4885TSHR 3233/4885 |
| US-20160220633-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | ALDH1A1 1076/4885KDM4E 1883/4885TSHR 3768/4885 |
| US-20170190734-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | ALDH1A1 1076/4885KDM4E 1883/4885TSHR 3768/4885 |
| US-20220389310-A1 | LUMINESCENT MATERIALS AND METHODS THEREOF | TYR, GSTA2, CYBA | ALDH1A1 479/4885KDM4E 3167/4885TSHR 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.